No startup sector was fully immune from the 2022’s market uncertainty — besides possibly AI — however some proved extra resilient than others. Biotech was one of the lucky.
The sector recorded 1,054 U.S.-based offers in 2022, price a collective $30.7 billion, in line with Pitchbook information. Those figures fell in need of the 1,415 biotech offers struck in 2021 price a complete of $39 billion. But the declines weren’t the worst we discovered: Biotech confirmed a extra modest year-over-year decline in funding quantity (21%) than many different sectors together with fintech (37.7%), shopper tech (53%) and enterprise tech (33%).
Comparing any sector’s outcomes to 2021 is barely specious, as that yr was the height of the final startup growth. Compared to 2020’s extra conservative 1,143 biotech offers price $29.6 billion, final yr wrapped up on par.
U.S. biotech offers additionally set new data in 2022 for each median deal measurement, $33.5 million, and median valuation, $38 million.
Biotech buyers advised TechCrunch that whereas they undoubtedly felt the squeeze of the general financial circumstances final yr — and seen vacationer buyers shying away from the class, much like different sectors — many weren’t stunned that the class carried out higher than among the different extra buzzy industries for a few key causes.
